Update on the treatment of calcinosis in dermatomyositis;Atualização na terapêutica da calcinose em dermatomiosite

Revista Brasileira de Reumatologia

Volumn 53, Issue 2, 2013, Pages 211-214

  Shinjo, Samuel Katsuyuki ^a   De Souza, Fernando Henrique Carlos ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Calcinosis; Dermatomyositis; Review; Therapy

Indexed keywords

ABATACEPT; ALENDRONIC ACID; ALUMINUM HYDROXIDE; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DILTIAZEM; ETANERCEPT; ETIDRONIC ACID; IMMUNOGLOBULIN; INFLIXIMAB; MAGNESIUM HYDROXIDE; METHOTREXATE; METHYLPREDNISOLONE; PAMIDRONIC ACID; PROBENECID; SODIUM THIOSULFATE; TACROLIMUS; THALIDOMIDE; VITAMIN K GROUP; WARFARIN;

ARTICLE; CALCINOSIS; CHRONIC DISEASE; COMORBIDITY; DENSITOMETRY; DERMATOMYOSITIS; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; INFLAMMATION; JUVENILE DERMATOMYOSITIS; LOW DRUG DOSE; REMISSION; REPEATED DRUG DOSE; SKIN CALCIFICATION; SKIN ULCER; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

CALCINOSIS; DERMATOMYOSITIS; HUMANS;

EID: 84881510319     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0482-50042013000200009     Document Type: Review

References (51)

1. Walsh JS, Fairley JA. Calcifying disorders of skin. J Am Acad Dermatol. 1995;33(5Pt1):693-706.
2. Touart DM, Sau P. Cutaneous deposition diseases. Part II. J Am Acad Dermatol. 1998;39(4 Pt1):527-44.
3. Paul H, Reginato AJ, Schumacher HR. Alizarin red S staining as a screening test to detect calcium compounds in synovial fl uid. Arthritis Rheum. 1983;26(2):191-200.
4. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcifi cation. J Pediatr. 1983;103(6):882-8.
5. Sogabe T, Silva CA, Kiss MHB. Clinical and laboratory characteristics of 50 children with dermato/polymyositis. Rev Bras Reumatol. 1996;36:351-9.
6. Sallum AM, Kiss MH, Sachetti S, Resende MB, Moutinho KC, Carvalho M de S, et al. Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evoluative parameters of 35 patients. Arq Neuropsiquiatr. 2002;60(4):889-99.
7. Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res. 2010;62(1):63-72.
8. Eddy MC, Leelawattana R, McAlister WH, Whyte MP. Calcinosis universalis complicating juvenile dermatomyositis: resolution during probenecid therapy. J Clin Endocrinol Metab. 1997;82(11):3536-42.
9. Sewell JR, Liyanage B, Ansell BM. 1978 Calcinosis in juvenile dermatomyositis. Skeletal Radiol. 1978;3:137-43.
10. Muller DA, Winkelmann RK, Brunstig LA. Calcinosis in dermatomyositis. Arch Dermatol. 1959;79(6):669-73.
11. Weinel S, Callen JP. Calcinosis cutis complicating adult-onset dermatomyositis. Arch Dermatol. 2004;140(3):365-6.
12. Crowe WE. Dermatomyositis and polymyositis In: Gershwin ME, Robbins DL. Musculoskeletal diseases of children. New York: Grune & Stratton; 1983. p.113-37.
13. Pachman LM, Boskey AL. Clinical manifestations and pathogenesis of hydroxyapatite crystal deposition in juvenile dermatomyositis. Curr Rheumatol Rep. 2006;8(3):236-43.
14. Burgos-Vargas R, Vázquez-Mellado J, Gómez-Gordillo Y, Katona G. Clinical study of dermato/polymyositis with onset in childhood . Bol Med Hosp Infant Mex. 1987;44(8):463-70.
15. Miller LC, Michael AF, Kim Y. Childhood dermatomyositis. Clinical course and long-term follow-up. Clin Pediatr. 1987;26(11):561-6.
16. Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, et al. TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifi cations. Arthritis Rheum. 2000;43(10):2368-77.
17. Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr. 2001;138(5):763-6.
18. Pachman LM, Veis A, Stock S, Abbott K, Vicari F, Patel P, et al. Composition of calcifi cations in children with juvenile dermatomyositis: association with chronic cutaneous infl ammation. Arthritis Rheum. 2006;54(10):3345-50.
19. Gunawardena H, Wedderbun LR, Chinoy H, Betteridge ZE, North J, Ollier WER, et al. Juvenile dermatomyositis research group, UK and Ireland Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheumatism. 2009;60(6):1807-14.
20. Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002;47(4):505-11.
21. Callen JP. Dermatomyositis. Lancet 2000; 355 (9197):53-7.
22. Cassidy JT, Petty RE. Dermatomyositis. In: Pediatric rheumatology, 3rd ed. Philadelphia: W.B. Saunders Co. 1995; 323-64.
23. Wilsher ML, Holdaway IM, North JD. Hypercalcemia during resolution of calcinosis in juvenile dermatomyositis. Brit Med J (Clin Res Ed). 1984;288(6427):1345.
24. Ostrov BE, Goldsmith DP, Eichenfield AH, Athreya BH. Hypercalcemia during the resolution of calcinosis universalis in juvenile dermatomyositis. J Rheumatol. 1991;18(11):1730-4.
25. Ambler GR, Chaitow J, Rogers M, McDonald DW, Ouvrier RA. Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy. J Rheumatol. 2005;32(9):1837-9.
26. Mukamel M, Horev G, Mimouni M. New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment. J Pediatr. 2001;138(5):763-6.
27. Mori H, Okada Y, Yamaoka K, Saito K, Tanaka Y. Marked improvement of calcinosis in adult dermatomyositis with etidronate therapy. J Bone Miner Metab. 2012;30(1):114-8.
28. Metzger AL, Singer FR, Bluestone R, Pearson CM. Failure of disodium etidronate in calcinosis due to dermatomyositis and scleroderma. N Engl J Med. 1974;291(24):1294-6.
29. Marco Puche A, Calvo Penades I, Lopez Montesinos B. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis. Clin Exp Rheumatol. 2010;28(1):135-40.
30. Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A. Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate. Jt, Bone Spine. 2010;77(1):70-2.
31. Skuterud E, Sydnes OA, Haavik TK. 1981 Calcinosis in dermatomyositis treated with probenecid. Scand J Rheumatol. 1981;10(2):92-4.
32. Ansell BM. Treatment of dermatomyositis. Arthritis Rheum. 1977;20:341.
33. Ansell BM. Management of polymyositis and dermatomyositis. Clin Rheum Dis. 1984;10(1):205-13.
34. Fuchs D, Fruchter L, Fishel B, Holtzman M, Yaron M. Colchicine suppression of local infl ammation due to calcinosis in dermatomyositis and progressive systemic sclerosis. Clin Rheumatol. 1986;5(4):527-30.
35. Downey EC, Woolley MM, Hanson V. Required surgical therapy in the pediatric patient with dermatomyositis. Arch Surg. 1988;123(9):1117-20.
36. Ichiki Y, Akiyama T, Shimozawa N, Suzuki Y, Kondo N, Kitajima Y. An extremely severe case of cutaneous calcinosis with juvenile dermatomyositis, and successful treatment with diltiazem. Br J Dermatol. 2001;144(4):894-7.
37. Jiang X, Yi Q, Liu D, Wang S, Li L. A case of juvenile dermatomyositis with severe calcinosis and successful treatment with prednisone and diltiazem Int J Dermatol. 2011;50(1):74-7.
38. Oliveri MB, Palermo R, Mautalen C, Hübscher O. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis. J Rheumatol. 1996;23(12):2152-5.
39. Vinen CS, Patel S, Bruckner FE. Regression of calcinosis associated with adult dermatomyositis following diltiazem therapy. Rheumatology (Oxford). 2000;39(3):333-4.
40. Miyamae T, Sano F, Ozawa R, Imagawa T, Inayama Y, Yokota S. Effi cacy of thalidomide in a girl with infl ammatory calcinosis, a severe complication of juvenile dermatomyositis. Pediatr Rheumatol Online J. 2010;8(1):6.
41. Aihara Y, Mori M, Ibe M, Kuriyama T, Takahashi Y, Shimizu C, et al. A case of juvenile dermatomyositis with calcinosis universalis-remarkable improvement with aluminum hydroxide therapy. Ryumachi. 1994;34(5):879-84.
42. Nakagawa T, Takaiwa T. Calcinosis cutis in juvenile dermatomyositis responsive to aluminum hydroxide treatment. J Dermatol. 1993;20(9):558-60.
43. Wang WJ, Lo WL, Wong CK. Calcinosis cutis in juvenile dermatomyositis: remarkable response to aluminum hydroxide therapy. Arch Dermatol. 1988;124(11):1721-2.
44. Nassim JR, Connolly CK. Treatment of calcinosis universalis with aluminium hydroxide. Arch Dis Child. 1970;45(239):118-21.
45. Berger RG, Featherstone GL, Raasch RH, McCartney WH, Hadler NM. Treatment of calcinosis universalis with low-dose warfarin. Am J Med. 1998;83(1):72-6.
46. Matsuoka Y, Miyajima S, Okada N. A case of calcinosis universalis successfully treated with low-dose warfarin. J Dermatol. 1998;25(11):716-20.
47. Al-Mayouf SM, Alsonbul A, Alismail K. Localized calcinosis in juvenile dermatomyositis: successful treatment with intralesional corticosteroids injection. Int J Rheumatic Dis. 2010;13(3):e26-e28.
48. Jashin J, Bradie J, Metz MD. Calcinosis Cutis of Juvenile Dermatomyositis Treated with Incision and Drainage Dermatol Surg. 2008;34(4):575-7.
49. Vitale A, Delia G, La Torre F, Calcagno G, D Alcontres FS. Massive gluteal calcinosis in a 10-year-old girl with juvenile dermatomyositis: successful surgical management. Plast Reconstr Surg. 2009;124(6):456e-8e.
50. Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infl iximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford). 2008;47(6):877-80.
51. Arabshahi B, Silverman RA, Jones OY, Rider LG. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr. 2012;160(3):520-2.